UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/575,491	04/12/2006	Kenichi Matsunaga	358275.20028	1571
38327 REED SMITH	7590 06/26/200 LLP	EXAMINER		
	W PARK DRIVE, SUI	GODDARD, LAURA B		
FALLS CHURCH, VA 22042			ART UNIT	PAPER NUMBER
			1642	
			MAIL DATE	DELIVERY MODE
			06/26/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)			
	10/575,491	MATSUNAGA ET AL.			
Office Action Summary	Examiner	Art Unit			
	LAURA B. GODDARD	1642			
The MAILING DATE of this communication app	pears on the cover sheet with the c	orrespondence address			
Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA.  - Extensions of time may be available under the provisions of 37 CFR 1.1: after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period v. Failure to reply within the set or extended period for reply will, by statute. Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim vill apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).			
Status					
1)⊠ Responsive to communication(s) filed on 12 A	pril 2006				
• • • • • • • • • • • • • • • • • • • •	action is non-final.				
3) Since this application is in condition for allowar		secution as to the merits is			
closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims					
4)⊠ Claim(s) <u>1-12</u> is/are pending in the application.					
4a) Of the above claim(s) is/are withdrawn from consideration.					
5) Claim(s) is/are allowed.					
6) Claim(s) is/are allowed.					
7) Claim(s) is/are rejected. 7) Claim(s) is/are objected to.					
8) Claim(s) <u>1-12</u> are subject to restriction and/or e	election requirement.				
Application Papers	·				
··· _					
9) The specification is objected to by the Examine					
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.					
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).  11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.					
	anniner. Note the attached Office	Action of form PTO-132.			
Priority under 35 U.S.C. § 119					
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).					
a) All b) Some * c) None of:					
1. Certified copies of the priority documents have been received.					
2. Certified copies of the priority documents have been received in Application No					
3. Copies of the certified copies of the priority documents have been received in this National Stage					
application from the International Bureau (PCT Rule 17.2(a)).					
* See the attached detailed Office action for a list	of the certified copies not receive	d.			
Attachment(s)	"□····-	(770 440)			
Notice of References Cited (PTO-892)     Notice of Draftsperson's Patent Drawing Review (PTO-948)	4) ∐ Interview Summary Paper No(s)/Mail Da				
3) Information Disclosure Statement(s) (PTO/SB/08)	5) Notice of Informal P				
Paper No(s)/Mail Date	6)  Other:				

## Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-6, drawn to the special technical feature of a glycoprotein having the following properties: molecular weight approximately 60kDa and ratio of carbohydrate content to protein content:16.4:1.0, extracted from *Tricholoma matsutake*.

Group II, claim(s) 7, drawn to the special technical feature of a method for an immune enhancement comprising administering to a subject the glycoprotein of claim 1 or 2.

Group III, claim(s) 8, drawn to the special technical feature of a method for promoting a recovery from stress, comprising administering to a subject the glycoprotein of claim 1 or 2.

Group IV, claim(s) 9, drawn to the special technical feature of a method for treating of preventing a tumor comprising administering to a subject the glycoprotein of claim 1 or 2.

Group V, claim(s) 10-12, drawn to the special technical feature of use of the glycoprotein of claim 1 or 2 for manufacture of an immune enhancing agent, agent for promoting a recovery from stress, or antitumor agent.

The inventions listed as Groups I-V do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The technical feature linking Groups I-V appears to be a glycoprotein of about 60 kDa, having a ratio of 16.4:1.0 carbohydrate:protein, and extracted from *Tricholoma matsutake*.

However, said technical feature does <u>not</u> constitute a special technical feature in view of US Patent Application Publication 2003/0180901, Matsunaga, filed October 10, 2001, published September 25, 2003 and Ishihara et al (Stress, June 2003, vol. 6, p. 141-148). Matsunaga teach extracting a dried protein product from *Tricholoma matsutake* using hot water or an alkaline solution, that has antitumor and stress recovery properties (abstract; [0002]; [0023-0042]; Examples 1-3; Table 4; [0159]). Ishihara et al also teach extracting a dried protein product from *Tricholoma matsutake*, CM6271, that is a biological response modifier or stress-reducer (abstract; p. 142, col. 1; p. 143, col. 1). Each of these references teach a protein composition extracted from *Tricholoma matsutake* that inherently comprises the claimed glycoprotein. The reference does not specifically teach that the composition comprises the glycoprotein

with characteristics of being 60 kDa or having a 16.4:1.0 carbohydrate:protein ratio. However, given the antitumor and stress-reducing properties of prior art composition, and given the prior art composition is isolated from the same *Tricholoma matsutake*, the claimed glycoprotein appears to be the same protein comprised in the prior art Tricholoma matsutake extract, absent a showing of unobvious differences. The office does not have the facilities and resources to provide the factual evidence needed in order to establish that the product of the prior art does not possess the same material, structural and functional characteristics of the claimed product. In the absence of evidence to the contrary, the burden is on the applicant to prove that the claimed product is different from those taught by the prior art and to establish patentable differences. See In re Best 562F.2d 1252, 195 USPQ 430 (CCPA 1977) and Ex parte Gray 10 USPQ 2d 1922 (PTO Bd. Pat. App. & Int. 1989).

Page 4

Therefore, the technical feature linking the inventions of Groups I-V does not constitute a special technical feature as defined by PCT Rule 13.2 as it does not define a contribution over the prior art. Accordingly, Groups I-V are not so linked by the same or a corresponding special technical feature as to form a single general incentive concept and restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the

Page 5

requirement may be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To preserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and the product claims are subsequently found allowable, withdrawn process claims that depend from or otherwise require all the limitations of the allowable product claim will be considered for rejoinder.

All claims directed to a nonelected process invention must require all the limitations of an allowable product claim for that process invention to be rejoined.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to

Application/Control Number: 10/575,491

Page 6

Art Unit: 1642

be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103 and 112. Until all claims to the elected product are found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowable product claim will not be rejoined. See MPEP § 821.04(b). Additionally, in order to retain the right to rejoinder in accordance with the above policy, applicant is advised that the process claims should be amended during prosecution to require the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder. Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to LAURA B. GODDARD whose telephone number is (571)272-8788. The examiner can normally be reached on 7:00am-3:30pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Larry Helms can be reached on 571-272-0832. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/575,491 Page 7

Art Unit: 1642

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Laura B Goddard/ Examiner, Art Unit 1642